Kynurenic Acid Offers Added Value in Predicting ECT Outcomes in Depression
Neuropsychobiology · 18.06.2026 · 1-14
DOI: 10.1159/000552240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychobiology, online erschienen am 18.06.2026. Verfasst von Annelies Dellink und 7 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium, annelies…. Hauptthemen laut MEDLINE: Kynurenic Acid, Electroconvulsive Therapy, Major Depressive Disorder. Die Arbeit nennt 83 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Introduction
Electroconvulsive therapy (ECT) is among the most effective treatments for severe depression, yet determining who will benefit remains challenging due to the lack of reliable predictors of treatment response. While clinical characteristics such as higher age and psychotic features are associated with increased odds of treatment success, their limited predictive value underscores the need for multimodal prediction models that integrate biological markers. Identifying such predictive biomarkers could facilitate a more personalized treatment strategy, optimize patient selection and increase ECT response rates.
Methods
In this prospective cohort study (n = 74), we developed multivariable linear and logistic regression models to assess the predictive value of plasma immune markers and their added contribution to clinical prediction models for ECT outcomes. Depressive symptom reduction was measured using the Inventory of Depressive Symptomatology (IDS-C).
Results
Kynurenic acid (KYNA) emerged as a significant predictor of the percentage symptom reduction and remission after ECT and significantly improved the prediction of response when added to clinical predictors. Subgroup analyses revealed stronger predictive value for KYNA in unipolar depression, males, and patients without comorbid inflammation (i.e., without acute infections or chronic inflammatory disease), suggesting its relevance in specific patient populations.
Conclusion
KYNA shows promise as a predictive biomarker for ECT outcomes. Future research should validate its robustness across diverse cohorts and patient subgroups to enable its clinical integration into personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium, annelies.dellink@gmail.com.
- Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium, annelies.dellink@gmail.com.
- Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- Department of Neurosciences, University Psychiatric Center KU Leuven, Research Group Psychiatry, Academic Center for ECT and Neuromodulation (AcCENT), Leuven, Belgium.
- KU Leuven, Department of Neurosciences, Psychiatry, Leuven, Belgium.
- Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium.
Zitieren
APA
Dellink, A., Belge, J. B., Sienaert, P., Lambrichts, S., Schrijvers, D., Van Diermen, L., Morrens, M., & Coppens, V. (2026). Kynurenic Acid Offers Added Value in Predicting ECT Outcomes in Depression. Neuropsychobiology, 1-14. https://doi.org/10.1159/000552240
Vancouver
Dellink A, Belge JB, Sienaert P, Lambrichts S, Schrijvers D, Van Diermen L, et al. Kynurenic Acid Offers Added Value in Predicting ECT Outcomes in Depression. Neuropsychobiology. 2026:1-14. doi:10.1159/000552240
BibTeX
@article{Dellink2026,
author = {Dellink, Annelies and Belge, Jean-Baptiste and Sienaert, Pascal and Lambrichts, Simon and Schrijvers, Didier and Van Diermen, Linda and Morrens, Manuel and Coppens, Violette},
title = {Kynurenic Acid Offers Added Value in Predicting ECT Outcomes in Depression},
journal = {Neuropsychobiology},
year = {2026},
pages = {1--14},
doi = {10.1159/000552240}
}
EUVIMED